| Title: |
Metabolic Syndrome and Psoriatic Arthritis:The Role Of Weight Loss As A Disease-Modifying Therapy |
| Authors: |
Corum Williams, Jacob; Hum, Ryan Malcolm; Rogers, Kira; Maglio, Cristina; Alam, Uazman; Zhao, Sizheng Steven |
| Source: |
Corum Williams, J, Hum, R M, Rogers, K, Maglio, C, Alam, U & Zhao, S S 2024, 'Metabolic Syndrome and Psoriatic Arthritis : The Role Of Weight Loss As A Disease-Modifying Therapy', Therapeutic Advances in Musculoskeletal Disease. |
| Publication Year: |
2024 |
| Collection: |
The University of Manchester: Research Explorer - Publications |
| Description: |
Psoriatic arthritis (PsA) is an inflammatory joint and entheseal disease associated with significant personal and public health burden. PsA has a prevalence of up to 1%, affecting ~20% of people suffering with psoriasis. PsA is frequently accompanied by metabolic syndrome (MetS), and both conditions are characterised by a chronic pro-inflammatory state, with several key cytokines in PsA (IL-17 and IL-23) also elevated in those with MetS. This narrative review aims to provide an update on MetS in PsA, focusing on its prevalence, pathogenesis, prognosis, treatment interactions and future therapeutic options MetS is particularly prevalent in PsA compared to other inflammatory arthritides. Cohort studies indicate a higher risk of PsA in individuals with obesity, while Mendelian randomization studies link childhood obesity, insulin resistance, and dyslipidaemia to PsA. Weight loss interventions have been shown to reduce disease activity in PsA. Additionally, MetS negatively impacts the efficacy of tumour necrosis factor inhibitor (TNFi) drugs in treating PsA. Drugs given for PsA may also affect the conditions constituting MetS. Leflunomide has been shown to reduce body weight but also increase blood pressure. TNFi drugs lead to weight gain but reduce cardiovascular risk. Janus kinase inhibitors (JAKi) increase lipid levels and cardiovascular risk among high-risk groups. Anti-IL-17 and anti-IL-12/IL-23 drugs may cause a short-term increase in cardiovascular risk, although the long-term effects have yet to be established. Weight loss represents an unexplored avenue for disease modification in PsA, alongside a plethora of general health benefits. Dietary and exercise modifications are the cornerstone of weight management but vary substantially across individuals. Novel therapies to treat weight loss, such as GLP-1 agonists and SGLT2 inhibitors, may prove useful alongside disease-modifying therapies for those with PsA and MetS and should be investigated as potential therapeutic adjuncts. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Availability: |
https://research.manchester.ac.uk/en/publications/88bfbc41-3b14-486f-9536-8b1a0091dd78 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| Accession Number: |
edsbas.98E1528 |
| Database: |
BASE |